About Pepper Bio

Pepper Bio utilizes a transomic platform that integrates phosphoproteomics, proteomics, transcriptomics, and genomics to identify new drug targets and predict patient responses for previously untreatable diseases. The company focuses on developing effective treatments for aggressive cancers and other complex conditions by providing actionable insights into biological mechanisms.

```xml <problem> Current drug discovery processes for aggressive cancers and other complex conditions often fail to identify effective treatments due to an incomplete understanding of the underlying biological mechanisms and patient-specific responses. Traditional methods struggle to integrate the vast amounts of omic data needed to reveal actionable insights for novel drug development and patient stratification. </problem> <solution> Pepper Bio offers a transomic platform that integrates phosphoproteomics, proteomics, transcriptomics, and genomics data to provide a comprehensive understanding of disease biology and drug mechanisms. The platform, called COMPASS, leverages machine learning to analyze a proprietary transomics database, identifying new drug targets and predicting patient responses for previously untreatable diseases. By capturing global, functional, and causative data, Pepper Bio's approach aims to accelerate drug discovery, enable patient stratification, and unlock greater commercial opportunities through biomarker and target identification, indication expansion, drug combinations, and lead optimization. The company is currently developing novel drug programs, including four in current development, and partners with R&D teams to advance their business. </solution> <features> - Integrates phosphoproteomics, proteomics, transcriptomics, and genomics data for a comprehensive view of disease biology. - Machine learning-driven platform (COMPASS) identifies new drug targets and predicts patient responses. - Proprietary transomics database built from pre-clinical discovery in untreatable cancers. - Identifies biomarkers for patient stratification and indication expansion. - Facilitates target identification and lead optimization for drug development. - Supports drug combination strategies. - Aims to provide an end-to-end, repeatable drug development process. </features> <target_audience> Pepper Bio's primary customers are pharmaceutical and biotech companies, as well as R&D teams, seeking to improve their drug discovery process, identify new drug targets, and develop effective treatments for aggressive cancers and other complex conditions. </target_audience> ```

What does Pepper Bio do?

Where is Pepper Bio located?

Pepper Bio is based in Boston, United States.

How much funding has Pepper Bio raised?

Pepper Bio has raised 11270000.

Location

Boston, United States

Funding

11270000

Employees

8 employees

Major Investors

NFX

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Pepper Bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

pepper.bio 1K+

Crunchbase

Boston, United States

Funding

Estimated Funding

$10M+

Major Investors

NFX

Team (5+)

No team information available.

Company Description

Problem

Current drug discovery processes for aggressive cancers and other complex conditions often fail to identify effective treatments due to an incomplete understanding of the underlying biological mechanisms and patient-specific responses. Traditional methods struggle to integrate the vast amounts of omic data needed to reveal actionable insights for novel drug development and patient stratification.

Solution

Pepper Bio offers a transomic platform that integrates phosphoproteomics, proteomics, transcriptomics, and genomics data to provide a comprehensive understanding of disease biology and drug mechanisms. The platform, called COMPASS, leverages machine learning to analyze a proprietary transomics database, identifying new drug targets and predicting patient responses for previously untreatable diseases. By capturing global, functional, and causative data, Pepper Bio's approach aims to accelerate drug discovery, enable patient stratification, and unlock greater commercial opportunities through biomarker and target identification, indication expansion, drug combinations, and lead optimization. The company is currently developing novel drug programs, including four in current development, and partners with R&D teams to advance their business.

Features

Integrates phosphoproteomics, proteomics, transcriptomics, and genomics data for a comprehensive view of disease biology.

Machine learning-driven platform (COMPASS) identifies new drug targets and predicts patient responses.

Proprietary transomics database built from pre-clinical discovery in untreatable cancers.

Identifies biomarkers for patient stratification and indication expansion.

Facilitates target identification and lead optimization for drug development.

Supports drug combination strategies.

Aims to provide an end-to-end, repeatable drug development process.

Target Audience

Pepper Bio's primary customers are pharmaceutical and biotech companies, as well as R&D teams, seeking to improve their drug discovery process, identify new drug targets, and develop effective treatments for aggressive cancers and other complex conditions.